Title:
VACCINE COMPOSITION
Document Type and Number:
WIPO Patent Application WO/2019/045025
Kind Code:
A1
Abstract:
Provided is a vaccine composition for treating or preventing a cancer with VASH2 expression, said vaccine composition containing a peptide which comprises the amino acid sequence represented by SEQ ID NO: 4.
Inventors:
SATO YASUFUMI (JP)
NAKAGAMI HIRONORI (JP)
TOMIOKA HIDEKI (JP)
NAKAGAMI HIRONORI (JP)
TOMIOKA HIDEKI (JP)
Application Number:
PCT/JP2018/032276
Publication Date:
March 07, 2019
Filing Date:
August 30, 2018
Export Citation:
Assignee:
UNIV TOHOKU (JP)
UNIV OSAKA (JP)
FUNPEP CO LTD (JP)
UNIV OSAKA (JP)
FUNPEP CO LTD (JP)
International Classes:
A61K39/00; A61K38/16; A61K38/17; A61K38/38; A61K47/64; A61P35/00; A61P37/04; C07K14/47; C07K16/18; C07K19/00; C12N15/09
Domestic Patent References:
| WO2006073052A1 | 2006-07-13 | |||
| WO2014087810A1 | 2014-06-12 | |||
| WO2014087810A1 | 2014-06-12 | |||
| WO2016047763A1 | 2016-03-31 |
Foreign References:
| JP2015077139W | 2015-09-25 | |||
| US201515514310A | 2015-09-25 | |||
| JP2017166860A | 2017-09-21 |
Other References:
LEE, EUN-SEO ET AL.: "Development of future antibody therapy with Vasohibin-2 serving as molecular target", 22ND ANNUAL MEETING OF THE JAPANESE SOCIETY FOR MOLECULAR TARGET THERAPY; MAY 16-18, 2018, 16 April 2018 (2018-04-16), pages 69, XP009519643
LEE, EUN-SEO: "Development of a novel and feasible antibody therapy targeting vasohibin-2", ABSTRACTS OF THE 76TH ANNUAL MEETING OF THE JAPANESE CANCER ASSOCIATION, 28 September 2017 (2017-09-28), pages 286, XP009519687, Retrieved from the Internet
SUN, JIE ET AL.: "Generation and characterization of rabbit polyclonal antibodies against Vasohibin-2 for determination of its intracellular localization", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 43, 24 April 2013 (2013-04-24), pages 255 - 261, XP055264846, DOI: 10.3892/ijo.2013.1919 r
KOYANAGI, TAKAHIRO ET AL.: "Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment", CANCER SCIENCE, vol. 108, no. 3, March 2017 (2017-03-01) - 3 April 2017 (2017-04-03), pages 512 - 519, XP055580209
MIYAZAKI, YASUMASA ET AL.: "A new strategy for the treatment of prostate cancer by targeting vasohibin-2", J UROLOGY, vol. 195, no. 4S, 2016, pages e1148, XP029477175
TU, MIN ET AL.: "Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via jun proto- oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2", MOLECULAR CANCER, vol. 16, no. 66, 21 March 2017 (2017-03-21), pages 1 - 12, XP055580216, ISSN: 1476-4598, DOI: 10.1186/s12943-017-0619-6
KIM JC ET AL., HEPATOGASTROENTEROLOGY, vol. 62, no. 138, March 2015 (2015-03-01), pages 251 - 6
HAMADA S ET AL.: "Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis", CARCINOGENESIS, vol. 38, 2017, pages 661 - 670
See also references of EP 3677276A4
LEE, EUN-SEO: "Development of a novel and feasible antibody therapy targeting vasohibin-2", ABSTRACTS OF THE 76TH ANNUAL MEETING OF THE JAPANESE CANCER ASSOCIATION, 28 September 2017 (2017-09-28), pages 286, XP009519687, Retrieved from the Internet
SUN, JIE ET AL.: "Generation and characterization of rabbit polyclonal antibodies against Vasohibin-2 for determination of its intracellular localization", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 43, 24 April 2013 (2013-04-24), pages 255 - 261, XP055264846, DOI: 10.3892/ijo.2013.1919 r
KOYANAGI, TAKAHIRO ET AL.: "Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment", CANCER SCIENCE, vol. 108, no. 3, March 2017 (2017-03-01) - 3 April 2017 (2017-04-03), pages 512 - 519, XP055580209
MIYAZAKI, YASUMASA ET AL.: "A new strategy for the treatment of prostate cancer by targeting vasohibin-2", J UROLOGY, vol. 195, no. 4S, 2016, pages e1148, XP029477175
TU, MIN ET AL.: "Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via jun proto- oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2", MOLECULAR CANCER, vol. 16, no. 66, 21 March 2017 (2017-03-21), pages 1 - 12, XP055580216, ISSN: 1476-4598, DOI: 10.1186/s12943-017-0619-6
KIM JC ET AL., HEPATOGASTROENTEROLOGY, vol. 62, no. 138, March 2015 (2015-03-01), pages 251 - 6
HAMADA S ET AL.: "Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis", CARCINOGENESIS, vol. 38, 2017, pages 661 - 670
See also references of EP 3677276A4
Attorney, Agent or Firm:
TAKASHIMA, Hajime et al. (JP)
Download PDF: